Landscape Capital Management L.L.C. Invests $461,000 in Glaukos Co. (NYSE:GKOS)

Landscape Capital Management L.L.C. purchased a new position in shares of Glaukos Co. (NYSE:GKOS - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 3,075 shares of the medical instruments supplier's stock, valued at approximately $461,000.

Several other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in Glaukos by 1.7% in the fourth quarter. Vanguard Group Inc. now owns 5,974,971 shares of the medical instruments supplier's stock valued at $895,887,000 after purchasing an additional 101,838 shares during the period. State Street Corp increased its position in Glaukos by 5.3% in the 3rd quarter. State Street Corp now owns 1,954,449 shares of the medical instruments supplier's stock valued at $254,626,000 after acquiring an additional 98,109 shares during the period. Geode Capital Management LLC raised its stake in Glaukos by 2.2% during the 4th quarter. Geode Capital Management LLC now owns 1,197,215 shares of the medical instruments supplier's stock valued at $179,555,000 after acquiring an additional 25,199 shares during the last quarter. Alliancebernstein L.P. raised its stake in Glaukos by 1,235.4% during the 4th quarter. Alliancebernstein L.P. now owns 816,153 shares of the medical instruments supplier's stock valued at $122,374,000 after acquiring an additional 755,035 shares during the last quarter. Finally, William Blair Investment Management LLC acquired a new stake in Glaukos during the 4th quarter worth approximately $121,390,000. Institutional investors and hedge funds own 99.04% of the company's stock.

Remove Ads

Analysts Set New Price Targets

Several research firms have recently commented on GKOS. Piper Sandler restated an "overweight" rating and set a $180.00 price target (up previously from $140.00) on shares of Glaukos in a research note on Monday, January 27th. Truist Financial cut their price objective on shares of Glaukos from $185.00 to $140.00 and set a "buy" rating for the company in a research report on Friday. Mizuho raised shares of Glaukos from a "neutral" rating to an "outperform" rating and lifted their target price for the company from $140.00 to $200.00 in a report on Wednesday, February 19th. Needham & Company LLC increased their price target on shares of Glaukos from $149.00 to $176.00 and gave the stock a "buy" rating in a report on Friday, February 21st. Finally, Wells Fargo & Company lifted their price objective on Glaukos from $153.00 to $160.00 and gave the company an "overweight" rating in a report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $159.50.

Glaukos Price Performance

NYSE:GKOS traded up $0.39 during trading hours on Friday, reaching $90.05. 533,122 shares of the company traded hands, compared to its average volume of 630,903. Glaukos Co. has a 1-year low of $77.91 and a 1-year high of $163.71. The stock has a market cap of $5.09 billion, a P/E ratio of -31.38 and a beta of 0.88. The firm's 50-day moving average is $114.19 and its 200-day moving average is $132.69. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71.

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.02). The firm had revenue of $105.50 million for the quarter, compared to analysts' expectations of $100.72 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. Equities research analysts expect that Glaukos Co. will post -1.08 earnings per share for the current fiscal year.

Insider Transactions at Glaukos

In other news, insider Tomas Navratil sold 3,416 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $147.14, for a total transaction of $502,630.24. Following the transaction, the insider now directly owns 72,437 shares in the company, valued at $10,658,380.18. This represents a 4.50 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Alex R. Thurman sold 1,520 shares of the business's stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total transaction of $162,396.80. Following the completion of the sale, the chief financial officer now owns 53,431 shares of the company's stock, valued at approximately $5,708,568.04. The trade was a 2.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 6.40% of the company's stock.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.